12.1% Average Loss With Semaglutide at 44 Weeks
STEP 7 studied weekly semaglutide 2.4 mg in a predominantly East Asian population with overweight or obesity. Its 44-week result is an average under the trial's eligibility, titration, lifestyle, and follow-up conditions—not a prediction for a particular person or program.
At week 44, estimated mean body-weight change was −12.1% with semaglutide 2.4 mg and −3.6% with placebo.
The estimated treatment difference was −8.5 percentage points. At least 5% weight loss occurred in 85% of semaglutide participants and 31% of placebo participants. Gastrointestinal disorders were reported in 67% and 36%, respectively.
Turn the study result into a better program comparison
If this result prompts you to compare GLP-1 programs, focus on practical factors the trial did not test: available plans, clinician access, medication status, follow-up, public price terms, and enrollment conditions. These reviewed brands have category-matched GLP-1 offers; none participated in or is endorsed by this study.
From $49 – $129/mo · Editorial score 4.7/5
Featured value terms: semaglutide $49/mo or tirzepatide $89/mo with 12-month prepayment; $99/$129 month to month.
We may earn a commission through provider links. Matching affiliate offers and editorial priorities affect inclusion and suggested order in commercial guides. Scores are not clinical endorsements. Disclosure · Methodology
Study details
- Population
- 375 adults with overweight or obesity, with or without type 2 diabetes; 72% were enrolled in mainland China, with additional sites in South Korea, Hong Kong, and Brazil
- Follow-up
- 44-week treatment period
- Treatment comparison
- Once-weekly subcutaneous semaglutide escalated to 2.4 mg compared with placebo, alongside a reduced-calorie diet and increased physical activity
- Study design
- Phase 3a, multicenter, double-blind, randomized, placebo-controlled trial
A study result is not a personal treatment plan
The trial does not determine whether semaglutide is appropriate for an individual, what a provider can prescribe, or what insurance covers. It studied a specific weekly 2.4 mg injectable regimen, not oral semaglutide, higher-dose products, or telehealth programs. Those decisions require a licensed clinician and current prescribing information.
Compare semaglutide and tirzepatide programsWhat this result does not show
- The 44-week duration does not establish long-term weight maintenance, results after stopping treatment, or uncommon or late adverse effects.
- The cohort was predominantly mainland Chinese and used WHO BMI thresholds, so results may not directly generalize to every population or care setting.
- The trial compared semaglutide with placebo, not another active weight-management medicine or another clinical-support model.
- It was not designed to compare telehealth providers, affordability, insurance coverage, pharmacy access, or individual treatment outcomes.
- Novo Nordisk funded the study, and author disclosures are reported in the peer-reviewed article.
Related Studies
Explore other peer-reviewed results in Evidence Watch before comparing programs or discussing options with a clinician.
Primary peer-reviewed source
Read the full paper, methodology, conflict-of-interest disclosures, and supplementary materials before drawing conclusions beyond this plain-English summary.
Read the study at The Lancet Diabetes & Endocrinology